Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Age: \> 18 years~* Gender: male / female~* Patients with an indication for liver resection (segmental or non-segmental)~* Willing and able to complete the clinical trial procedures, as described in the protocol~* Signed written informed consent to participate in this clinical trial~Exclusion:~* Presence or sequelae of coagulation disorder, liver cirrhosis, Klatskin tumor~* Concurrent participation in another clinical trial with a medical device or medicinal product or with interfering endpoints~* Concurrent or previous therapy with systemic pharmacologic agents promoting blood clotting including but not limited to tranexamix acid, activated factor VII, and aprotinine~* Known allergy or hypersensitivity to a component of the investigational treatments Sangustop® or TachoSil®, to riboflavin or to proteins of bovine origin~* Pregnancy or breast feeding~* Inability to understand the nature and the extent of the trial and the procedures required~* Missing signed written informed consent to participate in the study~Exclusion criteria to be checked during surgery (liver resection):~* Resection area estimated by operating surgeon \< 16cm2~* Infected wound area~* Persistant major bleeding after primary haemostasis~* No bleeding after resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sangustop (Type: EXPERIMENTAL): None
- Tachosil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).